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The classical autoimmunity paradigm in rheumatoid arthritis (RA) is strongly supported by immunogenetics
suggesting follicular helper T-cell responses driving high titre speciﬁc autoantibodies that pre-dates disease
onset. Using the immunological disease continuum model of inﬂammation against self with “pure” adaptive and
innate immune disease at opposite boundaries, we propose a novel immune mechanistic classiﬁcation describing
the heterogeneity within RA. Mutations or SNPs in autoinﬂammatory genes including MEFV and NOD2 are
linked to seronegative RA phenotypes including some so called palindromic RA cases. However, just as innate
and adaptive immunity are closely functionally integrated, some ACPA+ RA cases have superimposed “auto-
inﬂammatory” features including abrupt onset attacks, severe attacks, self-limiting attacks, relevant autoin-
ﬂammatory mutations or SNPs and therapeutic responses to autoinﬂammatory pathway therapies including
colchicine and IL-1 pathway blockade. An emergent feature from this classiﬁcation that non-destructive RA
phenotypes, both innate and adaptive, have disease epicentres situated in the extracapsular tissues. This mixed
innate and adaptive immunopathogenesis may be the key to understanding severe disease ﬂares, resistant dis-
ease subsets that are unresponsive to standard therapy and for therapies that target the autoinﬂammatory
component of disease that are not currently considered by expert therapeutic recommendations.
1. Background
The common clinical phenotype characterised by non-infectious
persistent polyarticular swelling, especially of small joints, that leads to
bone erosion and progressive joint destruction and deformity is known
as rheumatoid arthritis (RA) [1]. However, persistent periarticular sy-
novitis irrespective of the immunopathogenesis is associated with joint
erosion and destruction- so irrespective of the immune trigger the same
clinical phenotype emerges [2]. A logical extension of this view is that
immunologically diverse scenarios may be associated with the clinical
RA phenotype. An unmet need exists in the translational setting to
develop a robust paradigm for the assessment, diagnosis and prog-
nostication in patients that present with polyarthritis that is suggestive
of early RA, especially in the current era where the primary role of
innate immunity or autoinﬂammation is well recognised in other
chronic inﬂammatory diseases [3]. Using the paradigmatic shift that
occurred following the description of autoimmunity against
citrullinated antigens in many RA cases [4], we propose a novel clas-
siﬁcation for the full clinical disease spectrum of RA (Fig. 1). This im-
munological disease continuum model of inﬂammation in RA [5], has
implications for therapeutic strategies (Fig. 1).
2. Classical autoimmune RA
The recognition that anti-citrullinated protein antibodies (ACPA)
predate clinical RA in the majority of cases permitted disease classiﬁ-
cation in subjects with limited joint swelling [6,7]. That ACPA+ RA
represents a distinct entity that is strongly vindicated by genetic studies
demonstrating numerous genetic polymorphisms related to B and T
cells including MHC-II associations with such autoantibody positivity
[8,9]. Indeed, that ACPA+ disease is strongly associated with multiple
genetic abnormalities including PTPN22, CTLA4, CD40 and others that
ﬁrmly point towards genetic eﬀector mechanism upstream of the joint
in the lymphoid organs [10]. The preferential response of ACPA+ RA
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to B cell depletion therapeutically validates the autoimmune model
[11,12]. The co-occurrence of RF and ACPA+ status and worse prog-
nosis RA is conceptualised in terms of immune complex activation by
RF agglutination of ACPA+ immune complexes that lead to an increase
of pro-inﬂammatory cytokine production including TNF [13,14].
The preclinical phase in this autoimmune category of RA is related
to emergent synovitis, the synovium being considered the primary joint
target based on ultrasound, MRI and arthroscopic assessment [15,16].
The extra-articular disease features including nodulosis and lung in-
volvement are also understood in terms of protein citrullination, im-
mune complex formation at sites of either macrophage inﬁltration or
residence in the extra-synovial structures [17]. Recently, it has become
evident that ACPA are not the only autoimmunity players in RA and
emerging evidence for anti-CarP as important autoantibodies in RA but
these are usually present simultaneously with ACPA [18]. As in other
autoantibody associated diseases, the natural history of RA is char-
acterised by persistent inﬂammation until the target organ is com-
pletely destroyed [19]. Whilst RA may go into spontaneous remission
this is much less likely to occur in the ACPA+ or RF+ subgroup [20].
3. Other autoimmune forms of RA
Several other RA associated antibodies against modiﬁed protein
antigens that predate clinical disease, including the aforementioned
anti-carP autoantibodies, have been described thus supporting the idea
that early key events in the primary and secondary lymphoid organs
that house the adaptive immune system likely drive disease [21–23].
An ANA positive RA group without ACPA/RF is occasional reported
[24] (Fig. 1). This is strongly associated with anti-RA 33 antinuclear
antibodies with a speciﬁcity of for RA of 84.6%, and in the absence of
anti-U1-RNP antibodies, can be used as a serological marker for RA
[25] (Fig. 1).
Rheumatoid arthritis-like polysynovitis may be a feature of SLE and
other connective tissue diseases (CTDs) including dermatomyositis and
systemic sclerosis and undiﬀerentiated CTDs (UCTDs) [26]. Sometimes
a proportion of such cases fall under the “rhupus” umbrella [24,27].
This is viewed as an overlap type of disease or a form of UCTDs with
predominant RA pattern. In a patient presenting with ANA positive
synovitis, it is only with time that it may be possible to deﬁnitively
diagnose another category of arthritis (Fig. 1). On conventional radio-
graphy, ANA positive RA-like polysynovitis may evolve into a severe
deforming arthropathy but with minimal erosion termed Jaccound's
arthropathy. The basis for the generally less X-ray erosive phenotype of
SLE has been poorly understood [28–30], although recent MRI studies
also indicate a large burden of erosive disease in SLE [31].
4. Monogenic autoimmune rheumatoid arthritis
The immunological disease continuum model placed monogenic
forms of diseases at the two boundaries of pure autoimmune and pure
autoinﬂammatory disease (Fig. 1). At the present time, there is re-
markably little evidence for monogenic autoimmune RA. Possibly the
best illustrative example of monogenic autoimmune RA is cytotoxic T
lymphocyte antigen-4 (CTLA-4) haploinsuﬃciency. CTLA-4 helps to
control the magnitude of T cell activation and is also expressed on Tregs
where it is a key functional determinant of functional regulatory ac-
tivity. Patients with heterozygous autosomal dominant mutations in
CTLA-4 develop immune dysregulation and immunodeﬁciency syn-
drome due to reduced expression of functional CTLA-4 [32]. Recently, a
detailed description of 133 CTLA-4 mutation carriers, of which 90 in-
dividuals were thought to be clinically aﬀected has been published
[32]. This condition has a variable penetrance and the disease onset
varies between early childhood from age of 1 year to age of 59 with the
median age of 11. Interestingly, 3% had arthritis at the time of pre-
sentation, with one bone ﬁde RA case, and overall arthritis was seen in
14% of patients. These ﬁndings are in keeping with a notion that single
gene defects aﬀecting T cell tolerance might predispose to development
of RA, but this remains contentious given that the background
Fig. 1. Classiﬁcation of RA along the immunological disease continuum.
The RA phenotype is genetically and molecularly heterogeneous. Most cases have predominant autoimmunity but at the population level, there is great heterogeneity
with innate driven mechanisms. There is scarce evidence for monogenic forms of autoimmune RA but some evidence for autoinﬂammatory RA phenotypes. As shown,
a variable interaction between innate and adaptive immunity may operate in many cases and could be important for therapy stratiﬁcation in some cases.
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prevalence of RA is in the same range. Variants of NOD2 have also been
associated with a sporadic inﬂammatory arthritis than can be usually
diﬀerentiated form typical patterns of RA on clinica grounds [114].
5. Historical lessons showing innate immunity in RA pattern
disease
The concept of immunological disease heterogeneity within RA was
originally derived from the meticulous clinical observations by
Bywaters when he deﬁned Adult onset Still's Disease (AOSD) [33]. He
built a case stating that subjects with ASOD suﬀered from the paediatric
equivalent of Stills Disease (a type of juvenile rheumatoid arthritis).
Moreover, amongst other things, ASOD cases were RF negative and the
associated polysynovitis sometimes resolved spontaneously and
without joint destruction. Demonstrating scholarly foreknowledge,
Bywaters even commented that the spectrum of ASOD may merge with
a then little known entity called the Muckle-Wells syndrome (MWS)
[33]. Nowadays, joint inﬂammation in MWS is known to result from
gain of function mutations in the NLRP3 inﬂammasome leading to
constitutive hypersecretion of activated IL-1β with MWS being classi-
ﬁed as monogenic autoinﬂammatory diseases representing primary
innate immune dysregulation [34,35]. These comparative clinical
phenotypes between RA and polyarticular ASOD clearly deﬁne the
previously hidden heterogeneous nature of RA- a heterogeneity that
until now has not been exploited in the classiﬁcation of RA. According
to the genetically based mechanistic classiﬁcation of inﬂammation
against self, we conceptualised the heterogeneity of RA along an im-
munological disease continuum with some categories of RA were in fact
more likely to be driven by innate immunity and sit along a disease
continuum of separate clinical entities (Fig. 1) [5].
6. Monogenic autoinﬂammatory RA
Unlike adaptive immune mediated RA, the evidence for monogenic
autoinﬂammatory arthropathy manifesting as an RA is much more
compelling. For example, familial Mediterranean fever (FMF) is mainly
an autosomal recessive Mendelian condition and an archetypal auto-
inﬂammatory related to mutations in the MEFV gene leading to gain of
function in the pyrin protein that leads to aberrant activation of mul-
timeric protein complexes called inﬂammasome which is expressed
predominantly in neutrophils where it regulates inﬂammatory response
[36–38]. Moreover, heterozygous mutations in the MEFV gene were
strongly associated with seronegative RA in a Spanish cohort [39]. This
ﬁnding supports that the MEFV gene might participate in the patho-
genesis of other undiﬀerentiated relapsing inﬂammatory rheumatic
disorders [40].
Blau's syndrome is a monogenic autoinﬂammatory autosomal
dominant disease that may lead to a destructive RA like polyarthro-
pathy especially in the paediatric population where recognition as a
distinct entity is facilitated by granulomatosis uveitis and skin disease
[41,42]. The mutation underlying this RA-like phenotype is in NOD2
which is an intracellular NLR family receptor for bacterial cell wall
constituent muramyl dipeptide and it is evident that most of this group
with RA pattern polyarthritis lack ACPA antibodies [43–46].
7. The wider spectrum of seronegative RA
In the region of 20–40% of RA cases are ACPA negative [47]. Al-
lowing for the fact that some seronegative RA cases may have an un-
deﬁned relevant autoantibody, there is accumulating evidence sug-
gesting that non-Mendelian seronegative RA diverges from the classical
ACPA+ disease at multiple levels including the micro-anatomical basis
for disease (Fig. 2), genetic architecture, cellular pathology and even
therapeutic responsiveness [48–50]. The immunological disease het-
erogeneity in seronegative RA is supported by clinical outcomes in
patients developing polyarthritis can be extremely variable especially in
those with antibody negative disease who may have a better prognosis
[51,52].
Likewise, diseases including gout and pseudogout that can be mis-
diagnosed as RA have been linked at the molecular level to NLRP3
inﬂammasome activation [53]. Indeed, seronegative RA has a higher
burden of tissue urate acid crystal deposition compared to antibody
positive disease [54]. Taking cognizance of the fact that uric acid
crystals are powerful activators of the NLRP3 inﬂammasome supports
the idea that such IL-1β mechanisms might contribute to RA [55].
A small joint polysynovitis can occur in patients with psoriasis and
in patients whose ﬁrst degree relatives have psoriasis [56]. These are
deﬁned as psoriatic arthritis (PsA) and the vast majority of this group
are ACPA-negative indicating that they are not merely RA and co-in-
cidental psoriasis, a chance ﬁnding in the 1/10000 of the population
assuming a prevalence of 1% for RA and 2% for PsA [57]. At the po-
pulation level this small joint polysynovitis group are associated with
clinically unrecognised enthesitis in the swollen joints [58]. However,
this is not suﬃciently common to be diagnostically useful but points
towards an anatomical similarity. That common genetic associations
might contribute to these phenotypes is supported by the fact that
TNFAIP3 encoding for the A20 protein, a NF-kB regulatory protein is
associated with both PsA and RA [59]. However, at the present time,
the only clearly deﬁned diﬀerence is the presence of autoantibodies in
RA and the anatomical level diﬀerences centered on the enthesis in PsA
[58].
Polymyalgia rheumatica (PMR) may present with an RA pattern in
the elderly and it is characterised by polysynovitis [30,60]. However, it
typically has an abrupt onset and an ultimately good prognosis but on
occasion can be hard to tell from RA in “polymyalgic onset of RA”
[61,62]. Like in elderly patients with sudden onset polyarthritis, phy-
sicians may suspect a PMR type disease and consequently use low dose
steroids without consideration for disease-modifying anti-rheumatic
drugs (DMARDs) therapy. A scholarly evaluation of PMR recently
suggested that at the population level it sits closer to the innate immune
boundary of the immunological disease continuum [63]. Furthermore,
a clinicopathological entity termed remitting symmetrical seronegative
synovitis with pitting oedema (RS3PE) has features of RA but may ul-
timately have a good prognosis with an excellent therapeutic response
to low dose steroids [64,65].
8. Autoimmune-autoinﬂammatory overlap RA
In addition to population level diﬀerences in predominant auto-
immune or predominant innate immune mechanisms in the RA spec-
trum, a more complex interplay between both facets of the immune
system in disease expression, especially for clinically recaltricant cases
is now starting to emerge. Recently we reported 5 cases of seropositive
inﬂammatory arthritis case with the DRB1 shared epitope, who met the
EULAR/ACR diagnostic criteria for RA but who simultaneously ex-
hibited unusual clinical phenotypes resembling autoinﬂammatory dis-
ease [66]. They all had abrupt onset of synovitis with associated joint
erythema, excellent response to colchicine or IL-1 pathway antagonism
but poor response to conventional DMARDs. Mutations or SNPs in the
NLRP3, MEFV or NOD2 gene were evident in all but one of these cases.
Furthermore, a previous case of concomitant Muckle-Wells syndrome
and ACPA+ RA has been reported in the literature [66].
Beyond the genetics, the eﬀect of the autoinﬂammatory pathway
and NLRP3 is quite pervasive in RA [67]. For example, NLRP3 synovial
expression correlates with the clinical and radiological arthritis severity
in the collagen-induced model of arthritis [68]. In human studies, the
genetic variation in NLRP3 inﬂammasome components as well as
NLRP3 inﬂammasome activity have been shown to inﬂuence the sus-
ceptibility and severity of RA and response to conventional DMARDs
and TNFi therapy [69,70]. Also, in a joint immunology-rheumatology
autoinﬂammatory disease clinic we noted that some subjects previously
designated as seronegative RA whom we re-designated as undeﬁned
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systemic autoinﬂammatory disease exhibited good responses to IL-1
pathway antagonism [71].
9. Haploinsuﬃciency of A20 (HA20)- a unique link between
autoinﬂammatory and autoimmune RA
HA20 is a recently discovered monogenic autoinﬂammatory dis-
order resulting from high-penetrance heterozygous mutations in
TNFAIP3, which encodes the NF-κB regulatory protein A20 [72]. The
resulting haploinsuﬃciency of A20 is associated with inadequate in-
hibition of NF-κB pathway and excessive production of several pro-in-
ﬂammatory cytokines. However, unlike other monogenic autoin-
ﬂammatory disorders, HA20 seems to be associated with broad clinical
phenotypes, ranging from typical autoinﬂammatory conditions such as
JIA to more traditional autoimmune diseases such as SLE [73]. We have
recently described a family with a novel splicing mutation in TNFAIP3,
where the index case developed severe inﬂammatory arthritis within
the context of AOSD, whilst her father, who was also aﬀected, was di-
agnosed with classical RA [74]. A recent case series reported additional
RA cases complicating HA20 [73]. The clinical overlap between auto-
immune and autoinﬂammatory phenotypes seen in HA20 is perhaps not
too surprising considering that common variants in TNFAIP3 have also
been associated with several overlapping diseases including SLE, RA,
and psoriasis [75]. Haploinsuﬃcency of A20 was originally described in
a Behcets disease-like phenotypes [76] and it is noteworthy that at the
population level both Behcets and psoriasis have been classiﬁed as in-
termediate diseases between autoinﬂammation and autoimmunity
[5,77]. The evidence obtained from murine studies suggests that this
might be due to cell-speciﬁc eﬀects since selective A20 deﬁciency in
myeloid cells results in polyarthritis similar to RA in humans [78],
whilst deﬁciency in B cell or dendritic cell produces a tissue-dependent
response with the development of autoantibodies [79]. It is therefore
likely that additional factors, both environmental factors and epigenetic
cell type speciﬁc TNFAIP3 regulation could result in complex auto-
immune and innate immune dysregulation within the RA spectrum.
10. Microanatomy considerations that may help to explain RA
phenotypes
The immunological disease continuum model places an emphasis on
the microanatomical basis for disease localisation (Fig. 2). Remarkably,
there is evidence for anatomical compartmentalisation for both auto-
inﬂammatory spectrum and autoimmune RA that are linked to the
likelihood of destructive joint phenotypes based on intra-synovial or
extracapsular involvement. MRI studies have conﬁrmed prominent
capsular based inﬂammation in some ANA positive polysynovitis cases
which is very distinct from ACPA+ disease where disease involvement
is typically synovium centric [29,80]. This ANA positive category of RA
like disease, therefore, may have a distinct anatomical territory of in-
ﬂammation focussed on the extrapsular tissues. Indeed, these extra-
synovial signs of soft tissue pathology and less bony alterations help
explain Jaccoud's arthropathy phenotypes from classical forms of ero-
sive RA disease [80]. This anatomical compartmentalisation is also
evident in the RS3PE variant of RA which is also capsular based, but not
deforming and thought to be more autoinﬂammatory in nature since it
is a benign self-limiting polyarthritis [81]. Hence an anatomical epi-
centre of inﬂammation outside the synovial cavity may give clinical
joint swelling but without necessarily the joint destruction typical of the
classical ACPA+ RA.
11. Clinical considerations for early RA classiﬁcation
In the clinical setting, there are many features of RA in addition to
the diagnostic criteria that may inﬂuence a physician's approach to
disease therapy [82]. For example, patients that are autoantibody ne-
gative generally have less destructive disease [83–85]. An acute onset
Fig. 2. Microanatomical basis for the spectrum of RA phenotypes.
Although diﬀerent anatomical structures and cells are involved in RA pathogenesis, resident macrophages play the key role, maintaining the integrity of joints in
healthy subjects whereas in RA patients they exhibit pathological eﬀects. Pathological processes taking place in the juxta-articular tissues, capsule, synovium or
within ﬂuid and cartilage may lead to macrophage activation and then predictable periarticular destruction and the RA phenotype. The role of stromal cells as key
initiators in RA phenotypes awaits further study. The ACPA+RF+ group have the most severe and persistent inﬂammation and exhibit the most destructive
phenotype.
Note: A- Cartilage, B- Bone, C– Capsule, D- Fascia, E- Dermis and Epidermis.
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of disease may be associated ultimately with a good prognosis
(Table 1). In a patient with a sudden onset polyarthritis it may not be
possible to identify a speciﬁc viral trigger hence physicians may adopt a
wait and see approach.
12. Interplay between innate and adaptive immunity in the
pathogenesis of ACPA+ RA
As stated there is limited evidence for monogenic forms of pure
autoimmune RA in the literature. Clinical observations including the
non-placental transfer of RA strongly argue against a classical auto-
immune disease that is dependent to cardinal events occurring in the
primary and secondary lymphoid organs, with a subsequent attack on a
completely normal tissue [19]. Although autoimmune in nature, we
originally placed RA closer to the innate immune boundary than other
classically recognised autoimmune diseases [5]. It is now thought that
the initial phases of RA occur outside the primary and secondary lym-
phoid organs with non speciﬁc inﬂammation, likely prominent innate
immune related protein citrullination and other post-translational
modiﬁcations taking place at sites of tissue inﬂammation most notably
the periodontal tissues [86] and lungs [87] but other sites including the
gut and indeed the joint tissues themselves [8], where presumed in-
ﬂammation related citrullination may occur in OA [88–90]. These in-
itiating events rather than dysregulated central tolerance mechanism
likely culminate in shared epitope positive T-cells driving B-cell re-
sponses as indicated by higher titre autoantibodies is shared epitopes
(SE) alleles positive disease [91]. After disease localisation to the joints,
local ampliﬁcation of the autoimmunity occurs with higher titre pa-
thogenic antibodies consequent to the B cell and plasma cell protected
by synovial niches [89,92]. Finally, this process boomerangs back onto
innate immunity with citrullinated immune complexes activating Fc
receptor mediated myeloid cell activation and pivotal innate cytokine
production (Fig. 3) [92]. Consequently, for the classical autoimmune
form of RA there is ample non-speciﬁc innate immune activation con-
tributing to the initial events in post-translational protein modiﬁcations
at the outset and innate immune cell activation in the ﬁnal eﬀector
phase [93]. Beyond the recently recognised autoinﬂammatory genes
that could modify the classical autoimmune RA phenotype [94], a
myriad of other environmental, epigenomic and microbial factors may
inﬂuence disease [95–97]. Translational immunology observations
where TNFi is eﬀective in autoimmune RA [98] but not in other au-
toimmune humoral mediated diseases is consistent with this important
innate immune component in driving this autoimmune disease.
13. Fibroblast-like synovitis in RA
Stromal cells including synovial intimal ﬁbroblasts, subsynovial ﬁ-
broblasts and mesenchymal stem cells are abundant in the RA joint and
could also constitute local tissue speciﬁc auto-inﬂammatory mechan-
isms contributing to joint inﬂammation [99]. A role for stromal cells in
chronicity of autoimmunity is strongly suggested [100] but a direct role
for a primary ﬁbroblastic autoinﬂammatory RA phenotype is not suf-
ﬁciently established for inclusion in the classiﬁcation scheme at this
time (Fig. 1). However, in animal models, a speciﬁc role for stroma
related joint destruction, ostensibly independent of T and B cells was
demonstrated nearly 3 decades ago [101]. There is also evidence that
some cases of RA polyarticular synovitis have a ﬁbroblastic tissue
composition rather than the classical inﬂammatory component [102].
Studies are ongoing to determine whether such a phenotype might be
linked to therapy responses in RA and whether it supervenes on chronic
autoimmune ACPA+ RA or where it might represent a polyarticular
autoinﬂammatory disorder [103].
14. Therapeutic implications
A strong isolated autoinﬂammatory component or shared with
classical autoimmune RA may respond to agents such as colchicine or
interleukin-1 pathway blockade (Fig. 4). Indeed, in the clinical trial
program with IL-1 blockade, a subgroup of patients had impressive
ACR70 responses, which has never been fully understood [104], and in
another study the percentage of responders according to ACR50 was
signiﬁcantly higher in those treated with canakinumab than placebo
[115]. In the AOSD group the eﬃcacy of anakinra points towards a
fundamentally diﬀerent pathology from autoimmune RA where such
therapy does not work to the same degree [105]. Therefore, in cases of
RA which conventional therapy is not eﬀective, genotyping is abnormal
and clinical features of autoinﬂammatory disorders it is worthy to
consider agents that target the innate immunity such as colchicine, IL-1
antagonists or in the future potentially IL-18 blockers given that such
strategies are used in AOSD [106–111]. Therefore, therapeutic studies
clearly show that diseases under the historical uniform umbrella of
“RA” clinically, genetically and therapeutically ﬁt into the autoin-
ﬂammatory spectrum, even though the genetics of AOSD remain poorly
deﬁned (Fig. 4).
A signiﬁcant proportion of sporadic MWS patients have somatic
NLRP3 mutations with a variable degree of mosaicism [112]. It is
therefore possible that somatic mutations in key autoinﬂammatory
genes could also occur in autoantibody positive RA and profoundly
inﬂuence the disease phenotype. Indeed, genetically NLRP3 and other
autoinﬂammatory related gene SNPs have been reported in RA and
therefore might impact the joint involvement in such diseases leading
to RA-like disease (Fig. 5) [67]. Beyond NLR and RA, studies have also
reported the role of TLR2 and TLR4 function in RA pathogenesis, thus,
TLRs may be future potential therapeutic targets for RA [113]. Al-
though autoinﬂammatory or innate immune mechanisms are clearly
operational in classical autoimmune RA, the failure to anti-IL-1 therapy
Table 1
Pure adaptive and innate immune features of RA.
Adaptive immunity Innate immunity Mixed
Onset Typically, gradual Rapid Onset May have severe ﬂares on top of slow initial
evolutionLater age Early age
Acute ﬂares in established ACPA+ RA
Appearance Small joint synovitis Joint erythema and extracapsular
inﬂammation
Both
Theory Tolerance failure secondary to autoantibodies against
modiﬁed protein antigens
Danger Theory- site speciﬁc factor initiate
disease
Both concepts valid
Chief cellular players B and T cells Innate cells such as polymorphs
Genes MHC-II, CTLA-4, PTPN22, etc. MEFV, NLRP3 Interactions between both
Site of joint disease Usually in synovium May be capsular, extracapsular of synovial Mixed
Connective tissue disease RA pattern may be capsular
Therapy DMARDs, Anti-TNF, speciﬁc B cell and T cell targeting and
JAK inhibition
Colchicine and anti-IL-1
Systemic features Less likely More likely
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Fig. 3. Innate immunity in classical ACPA+ RA.
This ﬁgure shows how classical autoimmune related RA actually has pivotal tissue-speciﬁc innate immune events taking place in extra-articular and articular tissues
in the form of non-speciﬁc protein citrullination at sites of inﬂammation including the lungs, mouth, gut and joint. The biology of the adaptive immune system and
MHC-II related follicular T cell help for B cells and high titre autoantibody production is well understood and represents the cornerstone autoimmune mechanism in
most RA cases. This adaptive immunity is sandwiched between the aforementioned tissue speciﬁcity and subsequent innate immune activation due to the eﬀect of
immune complexes formation and interaction with myeloid lineage innate immune cells with resultant pro-inﬂammatory cytokine production. Features of this ﬁgure
are reproduced from https://smart.servier.com (Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License), and were
changed in terms of shape and size.
Fig. 4. How therapy helps to classify RA subgroups.
Classiﬁcation of RA according to the immunological disease continuum and the various components involved is reﬂected in diﬀerential therapeutic targeting. Given
the strong link between autoinﬂammatory RA and inﬂammasomes and the lack of dependence of IL-1 signaling on JAK-STAT pathway then it is unlikely that what is
considered pure autoinﬂammatory RA will respond to this pathway. Features of this ﬁgure are reproduced from https://smart.servier.com (Servier Medical Art by
Servier is licensed under a Creative Commons Attribution 3.0 Unported License), and were changed in terms of shape and size.
Abbreviations: MMF, mycophenolate mofetil; BAFF, B-cell activating factor; BP, IL-18BO, IL-18 binding protein; JAKi, JAK inhibitors; TNF, tumour necrosis factor;
DC, dendritic cells.
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with canakinumab attests to the population level predomenance of
autoimmune mechanisms.
15. Conclusions
The existing clinical classiﬁcation criteria for RA are partially based
on the adaptive immunity pathogenesis disease component including
RF and ACPA. The immunological disease continuum based classiﬁca-
tion described herein is relevant for therapy stratiﬁcation for diﬀerent
disease groups. The mechanistic immune classiﬁcation has implications
for understanding the complexity of RA and for thinking about therapy
in an immune centric way. It relies on clinical features of disease to help
identify heterogeneity within the disease.
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